Study of etentamig (ABBV-383) for AL amyloidosis
Part of Hormones & metabolism clinical trials.
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with primary systemic AL amyloidosis, a condition where abnormal proteins build up in your organs.
- You need to have at least one organ affected by the disease.
- You must have already tried a proteasome inhibitor (like bortezomib) and an anti-CD38 antibody (like daratumumab).
- You should not have symptomatic multiple myeloma, Waldenström's macroglobulinemia, or other non-AL amyloid conditions.
- You cannot have had major surgery in the last 28 days or an active infection needing intravenous treatment in the last 14 days.
- You should not have had a stem cell transplant within the last 12 weeks (autologous) or 1 year (allogeneic).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called etentamig against a standard combination therapy (Dara-CyBorD) for people with AL amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see which treatment better controls the disease and has fewer side effects.
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
This trial tests a new targeted medicine called elranatamab for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs. It aims to see if this treatment can help control the disease.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
Hear when a new Immunoglobulin Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.